Role of Bcl-2 -938 C&gt;A polymorphism in susceptibility and prognosis of cancer: a meta-analysis

Zhou, Xiao; Weng, Wenhao; Wen, Xin; Wang, Yulan; Yu, Wenjun; Tang, Xun; Ma, Lifang; Pan, Qiuhui; Wang, Jiayi; Sun, Fenyong

doi:10.1038/srep07241

Cited by 6 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The publication bias was examined by R ( http://cran.r-project.org/bin/windows/base ). To validate the association between miR-200c expression in blood and TNM stage, 1000 re-sampling groups were produced by the bootstrap re-sampling procedure[ 40 , 41 ]. The re-sampling statistic program was shown in S1 Excel File.…”

Section: Methodsmentioning

confidence: 99%

Prognostic Value and Clinicopathology Significance of MicroRNA-200c Expression in Cancer: A Meta-Analysis

Fang

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

MiR-200c has been shown to be related to cancer formation and progression. However, the prognostic and clinicopathologic significance of miR-200c expression in cancer remain inconclusive. We carried out this systematic review and meta-analysis to investigate the prognostic value of miR-200c expression in cancer. Pooled hazard ratios (HRs) of miR-200c for overall survival (OS) and progression-free survival (PFS) were calculated to measure the effective value of miR-200c expression on prognosis. The association between miR-200c expression and clinical significance was measured by odds ratios (ORs). Twenty-three studies were included in our meta-analysis. We found that miR-200c was not significantly correlated with OS (HR = 1.41, 95%Cl: 0.95-2.10; P = 0.09) and PFS (HR = 1.12, 95%Cl: 0.68-1.84; P = 0.67) in cancer. In our subgroup analysis, higher expression of miR-200c was significantly associated with poor OS in blood (HR = 2.10, 95%CI: 1.52-2.90, P<0.00001). Moreover, in clinicopathology analysis, miR-200c expression in blood was significantly associated with TNM stage, lymph node metastasis and distant metastasis. MiR-200c may have the potential to become a new blood biomarker to monitor cancer prognosis and progression.

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic Value and Clinicopathology Significance of MicroRNA-200c Expression in Cancer: A Meta-Analysis

Fang

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In other words, this SNP is associated with the development of leukemia in the cases under study. This finding was also seen in Asian inhabitants, but not in Caucasian populations (Zhang et al, 2014). BCl-2 gene variant polymorphism (rs2279115), genetic power, and HWE primarily rely on the sample magnitude, project design, and allele frequency in all groups (Evans & Purcell, 2012).…”

Section: Discussionmentioning

confidence: 88%

Genotyping of the BCL2 Gene Polymorphism rs2279115 Shows Associations with Eukemia Tendencies in the Iraqi Population

Al-Koofee¹,

Ismael²

2018

J Pure Appl Microbiol

View full text Add to dashboard Cite

The purpose of this study is to assess the SNP (rs2279115;-938 C>A) polymorphism in the BCL-2 gene of Iraqi leukemic patients. The B-cell lymphoma 2 (BCL-2) gene is considered to be related with leukemia improvement. The single nucleotide polymorphism "(SNP;-938 C>A)" of BCL-2 was discovered a few years ago. In accordance with the SNP's (rs2279115) function against leukemia, we evaluated the distribution frequency of the allele in addition to the relationship of the genotype with clinicopathological features. This study involved a case-control design in which the BCL-2 gene promoter polymorphism with the rs2279115 variant was genotyped in a total of 230 individuals, including 120 leukemia patients and 110 healthy subjects, to predict the variation in leukemic Iraqi patients. The patient group was enrolled from the Medical Euphrates Center for Oncology in the Najaf province that is involved in the WHO strategy of leukemia. From whole categories of blood, the DNA was extracted and genotyped using the BccI enzyme and the RFLP-PCR technique. The occurrences of the CC, AC, and AA alleles of the promoter BCL-2 gene polymorphism (C-938A) in leukemia patients were 38 (32%), 55 (46%), and 27 (22.5%), respectively, while control they were 46 (42%), 54 (49.1%), and 10 (9.1%), respectively in the control group (P<0.01). It was shown that the existence of the A allele in the SNP (rs2279115) in the BCL-2 gene promoter was related to an increased risk for the development of leukemia in the Iraqi population. The minor allele (A) in (rs2279115) of BCL-2 gene was significantly elevated (p<0.01) in leukemia patients (22.5%) as compared with healthy individuals (9.1%). Accordingly, the homozygous genotype AA (OR=3.27, CI 95% 1.41-7.60, P= 0.01) significantly augmented the risk of leukemia development by more than three times when compared with those of reference wild-type AA. The results of this study indicated that the AA genotype of BCL-2 (-938C>A) was associated with a predisposition to leukemia in the Iraqi population.

show abstract

“…The literature review was performed independently by X Zhang and J Wang and the disagreements were resolved through consensus by all the authors. 15 , 16…”

Section: Methodsmentioning

confidence: 99%

“…If articles provided insufficient data (missing data, inconsistencies, or any other uncertainties), we attempted to contact the first and corresponding authors for necessary information via telephone or email. 15 , 16…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The association between the migration inhibitory factor -173G/C polymorphism and cancer risk: a meta-analysis

Zhou¹,

Weng²,

Wen³

et al. 2015

OTT

Self Cite

View full text Add to dashboard Cite

Previous studies have suggested that macrophage migration inhibitory factor (MIF) −173G/C polymorphism may be associated with cancer risk. However, previous research has demonstrated conflicting results. Therefore, we followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and the meta-analysis on genetic association studies checklist, and performed a meta-analysis to investigate the association between MIF −173G/C polymorphisms and the risk of cancer. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were combined to measure the association between MIF promoter polymorphisms and cancer risk. The pooled ORs were performed for the dominant model, recessive model, allelic model, homozygote comparison, and heterozygote comparison. The publication bias was examined by Begg’s funnel plots and Egger’s test. A total of ten studies enrolling 2,203 cases and 2,805 controls met the inclusion criteria. MIF (−173G/C) polymorphism was significantly associated with increased cancer risk under the dominant model (OR=1.32, 95%, CI=1.00–1.74, P=0.01) and the heterozygote comparison (OR=1.38, CI=1.01–1.87, P=0.04). In subgroup analysis, MIF polymorphism and prostate were related to increased risk of prostate and non-solid cancer. In conclusion, MIF polymorphism was significantly associated with cancer risk in heterozygote comparison. The MIF −173G/C polymorphism may be associated with increased cancer risk.

show abstract

Role of Bcl-2 -938 C>A polymorphism in susceptibility and prognosis of cancer: a meta-analysis

Cited by 6 publications

References 46 publications

Prognostic Value and Clinicopathology Significance of MicroRNA-200c Expression in Cancer: A Meta-Analysis

Prognostic Value and Clinicopathology Significance of MicroRNA-200c Expression in Cancer: A Meta-Analysis

Genotyping of the BCL2 Gene Polymorphism rs2279115 Shows Associations with Eukemia Tendencies in the Iraqi Population

The association between the migration inhibitory factor -173G/C polymorphism and cancer risk: a meta-analysis

Contact Info

Product

Resources

About